Company research
Adagio Medical Holdings, Inc.
CIK 2006986Updated Sep 26, 2026
SecurityADGM · NASDAQ · equity
Name history
Aja Holdco, Inc. · through Aug 1, 2024
ADGM price & chart
Loading TradingView…
NASDAQ:ADGM on TradingView ↗About the company
Adagio is a medical device company focused on developing and commercializing products for the treatment of cardiac arrhythmias utilizing its novel, proprietary, catheter-based Ultra-Low temperature ablation (“ULTA”, formerly known as ULTC) technology. ULTA is designed to create large footprint, titratable lesions extending through the depth of both diseased and healthy cardiac tissue, all through an endocardial approach. The Company is currently focused on the treatment of ventricular arrhythmias with its purpose-built vCLAS Ventricular Ablation System, which is CE Marked, and in May 2026 the Company submitted the results of the FULCRUM-VT pivotal study to support its PMA application to the FDA for the vCLAS Ventricular Ablation System. The Company is also developing a next-generation vCLAS Ultra catheter, designed to support faster ablation procedures with a smaller and more flexible form factor than its predecessor vCLAS device.
In the news
No coverage from other publishers is available.
Recent filings
Costs Associated with Exit or Disposal Activities · Other Events
Items 2.05, 8.01, 9.01
SCHEDULE 13G/A filing
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Items 3.01
Regulation FD Disclosure
Items 7.01, 9.01
4 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| ASSETS | |||
| AssetsUSD | 43,253,000Source | 48,448,000Source | 6,825,000Source |
| Property, Plant and Equipment, NetUSD | 1,535,000Source | 1,961,000Source | 1,487,000Source |
| GoodwillUSD | 13,967,000Source | 13,967,000Source | 0Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 6,969,000Source | 6,969,000Source | 0Source |
| Current assets: | |||
| Cash and Cash Equivalents, at Carrying ValueUSD | 17,105,000Source | 20,586,000Source | 1,383,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | 35,000Source | 71,000Source |
| Inventory, NetUSD | 1,672,000Source | 2,566,000Source | 3,322,000Source |
| Assets, CurrentUSD | 20,082,000Source | 25,349,000Source | 5,185,000Source |
| Operating Lease, Right-of-Use AssetUSD | 697,000Source | 188,000Source | 130,000Source |
| Other Assets, NoncurrentUSD | 3,000Source | 14,000Source | 23,000Source |
| LIABILITIES AND EQUITY | |||
| LiabilitiesUSD | 30,851,000Source | 28,536,000Source | 47,379,000Source |
| Stockholders’ equity: | |||
| Common Stock, Value, IssuedUSD | 2,000Source | 2,000Source | 1,000Source |
| Additional Paid in CapitalUSD | 108,108,000Source | 90,495,000Source | 1,608,000Source |
| Retained Earnings (Accumulated Deficit)USD | -95,609,000Source | -70,586,000Source | -133,649,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -99,000Source | 1,000Source | 17,000Source |
| Stockholders' Equity Attributable to ParentUSD | 12,402,000Source | 19,912,000Source | -132,023,000Source |
| Liabilities and EquityUSD | 43,253,000Source | 48,448,000Source | 6,825,000Source |
| Current liabilities: | |||
| Liabilities, CurrentUSD | 8,233,000Source | 7,763,000Source | 47,176,000Source |
| Operating Lease, Liability, CurrentUSD | 155,000Source | 143,000Source | 79,000Source |
| Accounts Payable, CurrentUSD | 1,082,000Source | 2,840,000Source | 3,830,000Source |
| Operating Lease, Liability, NoncurrentUSD | 563,000Source | 46,000Source | 52,000Source |
| Deferred Income Tax Liabilities, NetUSD | 883,000Source | 883,000Source | — |
| Other Liabilities, NoncurrentUSD | — | 3,616,000Source | 8,000Source |
| Additional Financial Items | |||
| Accrued Liabilities, CurrentUSD | 6,996,000Source | 3,673,000Source | 3,048,000Source |
| Deferred Tax Liabilities, NetUSD | 882,000Source | 883,000Source | 0Source |
| Long-term DebtUSD | 21,040,000Source | 16,076,000Source | 38,268,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Cash flows from operating activities: | |||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -25,084,000Source | — | -36,590,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Depreciation, Depletion and AmortizationUSD | 970,000Source | — | 532,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 1,479,000Source | — | 442,000Source |
| Changes in operating assets and liabilities: | |||
| Increase (Decrease) in Accounts ReceivableUSD | -38,000Source | — | 70,000Source |
| Increase (Decrease) in InventoriesUSD | -931,000Source | — | 2,976,000Source |
| Increase (Decrease) in Accounts PayableUSD | -1,756,000Source | — | 2,821,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -19,014,000Source | — | -25,652,000Source |
| Cash flows from investing activities: | |||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -374,000Source | — | -340,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 374,000Source | — | 333,000Source |
| Cash flows from financing activities: | |||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 16,134,000Source | — | 21,875,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -3,481,000Source | — | -4,164,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 17,105,000Source | 35,154,000Source | 1,383,000Source |
| Supplemental disclosure of cash flow information: | |||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | 208,000Source |
| Additional Financial Items | |||
| Share-based Payment Arrangement, ExpenseUSD | 1,479,000Source | — | 442,000Source |
| Amortization of Intangible AssetsUSD | 0Source | — | — |
| DepreciationUSD | 900,000Source | — | 500,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | -3,000Source |
| GoodwillUSD | 13,967,000Source | — | 0Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | 0Source |
| Impairment of Intangible Assets, Finite-livedUSD | 0Source | — | 0Source |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | 0Source | — | 0Source |
| Income Tax Expense (Benefit)USD | 0Source | — | 0Source |
| InterestExpenseNonoperatingUSD | 2,906,000Source | — | 1,659,000Source |
| Inventory Write-downUSD | — | — | 25,000Source |
| Investment Income, InterestUSD | 477,000Source | — | 3,000Source |
| Net Income (Loss) Attributable to ParentUSD | -25,084,000Source | — | -36,590,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -25,084,000Source | — | -36,590,000Source |
| Nonoperating Income (Expense)USD | -3,194,000Source | — | -8,648,000Source |
| Operating Lease, ExpenseUSD | — | — | 159,000Source |
| Other Nonoperating Income (Expense)USD | 195,000Source | — | -20,000Source |
| Proceeds from Issuance of Common StockUSD | 16,134,000Source | — | — |
| Proceeds from Stock Options ExercisedUSD | — | — | 18,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2023 |
|---|---|---|
| Total RevenueUSD | 0Source | 300,000Source |
| Cost of Goods and Services Sold | — | — |
| Gross Profit (Calculated) · Derived | — | — |
| Selling, General and Administrative ExpenseUSD | 10,567,000Source | 11,537,000Source |
| Operating Income (Loss)USD | -21,890,000Source | -27,942,000Source |
| Other Nonoperating Income (Expense)USD | 195,000Source | -20,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -25,322,000Source | -36,590,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -25,084,000Source | -36,590,000Source |
| Earnings Per Share, BasicUSD per share | -1.51Source | -48.16Source |
| Earnings Per Share, DilutedUSD per share | -1.51Source | -48.16Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 16,577,126Source | 759,814Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 16,577,126Source | — |
| Interest Expense (non-operating)USD | 2,906,000Source | 1,659,000Source |
| Additional Financial Items | ||
| Amortization of Intangible AssetsUSD | 0Source | — |
| Common Stock, Dividends, Per Share, DeclaredUSD per share | — | 0Source |
| Costs and ExpensesUSD | 21,890,000Source | 28,242,000Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -25,239,000Source | -36,517,000Source |
| Investment Income, InterestUSD | 477,000Source | 3,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -25,084,000Source | -36,590,000Source |
| Nonoperating Income (Expense)USD | -3,194,000Source | -8,648,000Source |
| Operating Lease, ExpenseUSD | — | 159,000Source |
| Research and Development ExpenseUSD | 10,639,000Source | 15,399,000Source |
Offerings
Registration 333-284263
Registration 333-284266
Filing attachments
tm2623192d1_ex99-1.htm · 8-K · 2026-08-13
EX-99.1 2 tm2623192d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 1 August 2026 ─────────────── 2 - CONFIDENTIAL - Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding the potential of our Proprietary Ultra Low Temperature Cryoablation technology, the durability and reproducibility of …
Read attachment ↗tm2622801d1_ex99-1.htm · 8-K · 2026-08-11
EX-99.1 2 tm2622801d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Adagio Medical Reports Second Quarter 2026 Results LAGUNA HILLS, CA, August 11, 2026 - Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the second quarter ended June 30, 2026. Recent Business Highlights: Announced the successful treatment at the Hospital of University …
Read attachment ↗tm2614299d2_ex99-1.htm · 8-K · 2026-05-21
EX-99.1 2 tm2614299d2_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Adagio Medical Submits Premarket Approval Application to FDA for vCLAS® Ventricular Ablation System for the Treatment of Ventricular Tachycardia PMA Submission Supported by FULCRUM-VT Pivotal Trial Data - 209 Patients Across 20 Leading Centers; Breakthrough Device Designation Previously Granted Marks the First-Ever PMA Submission for a Purpose-Built VT Ablation System in a $5.8B Market LAGUNA HILLS, CA, May 21, 2026 - Adagio Med…
Read attachment ↗tm2614299d1_ex99-1.htm · 8-K · 2026-05-12
EX-99.1 2 tm2614299d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Adagio Medical Reports First Quarter 2026 Results and Meaningful Clinical Progress Advancing Toward Submission for PMA Approval Following Late-Breaking FULCRUM-VT Data LAGUNA HILLS, CA, May 12, 2026 - Adagio Medical Holdings, Inc (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the first quarter ended M…
Read attachment ↗tm2612751d1_ex99-1.htm · 8-K · 2026-04-27
EX-99.1 2 tm2612751d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Adagio Medical Announces Positive Pivotal Results for vCLAS® Ventricular Ablation System 84% Freedom From Shock and 59% Freedom from VT Recurrence in FULCRUM-VT Pivotal IDE Trial Meet Safety and Effectiveness Endpoints and Replicate CryoCure-VT Results First and Only Ablation Technology to Show Equivalent Effectiveness Across Ischemic and Non-Ischemic Cardiomyopathy all from Endocardial Approach LAGUNA HILLS, CA, April 26, 2026 -…
Read attachment ↗tm2611362d1_ex99-1.htm · 8-K · 2026-04-08
EX-99.1 2 tm2611362d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Adagio Medical Receives IDE Approval from the FDA to Investigate Next-Generation vCLAS® Ventricular Ablation System Designed to Deliver Faster, More Efficient Ablation with Improved Usability on Established, Titratable, Endocardial-Approach ULTA Platform LAGUNA HILLS, CA, April 8, 2026 - Adagio Medical Holdings, Inc (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment…
Read attachment ↗